Literature DB >> 12150871

TX-1123: an antitumor 2-hydroxyarylidene-4-cyclopentene-1,3-dione as a protein tyrosine kinase inhibitor having low mitochondrial toxicity.

Hitoshi Hori1, Hideko Nagasawa, Masaki Ishibashi, Yoshihiro Uto, Akihiko Hirata, Kouichi Saijo, Kazuto Ohkura, Kenneth L Kirk, Yoshimasa Uehara.   

Abstract

A series of 2-hydroxyarylidene-4-cyclopentene-1,3-diones were designed, synthesized, and evaluated with respect to protein tyrosine kinase (PTK) inhibition, mitochondrial toxicity, and antitumor activity. Our results show that the cyclopentenedione-derived TX-1123 is a more potent antitumor tyrphostin and also shows lower mitochondrial toxicity than the malononitrile-derived AG17, a potent antitumor tyrphostin. The O-methylation product of TX-1123 (TX-1925) retained its tyrphostin-like properties, including mitochondrial toxicity and antitumor activities. However, the methylation product of AG17 (TX-1927) retained its tyrphostin-like antitumor activities, but lost its mitochondrial toxicity. Our comprehensive evaluation of these agents with respect to protein tyrosine kinase inhibition, mitochondrial inhibition, antitumor activity, and hepatotoxicity demonstrates that PTK inhibitors TX-1123 and TX-1925 are more promising candidates for antitumor agents than tyrphostin AG17.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12150871     DOI: 10.1016/s0968-0896(02)00160-8

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  11 in total

1.  Novel etodolac derivatives as eukaryotic elongation factor 2 kinase (eEF2K) inhibitors for targeted cancer therapy.

Authors:  Ferah Comert Onder; Pinar Siyah; Serdar Durdagi; Mehmet Ay; Bulent Ozpolat
Journal:  RSC Med Chem       Date:  2022-06-02

2.  A Ca(2+)-calmodulin-eEF2K-eEF2 signalling cascade, but not AMPK, contributes to the suppression of skeletal muscle protein synthesis during contractions.

Authors:  Adam J Rose; Thomas J Alsted; Thomas E Jensen; J Bjarke Kobberø; Stine J Maarbjerg; Jørgen Jensen; Erik A Richter
Journal:  J Physiol       Date:  2009-02-02       Impact factor: 5.182

Review 3.  Eukaryotic elongation factor 2 kinase as a drug target in cancer, and in cardiovascular and neurodegenerative diseases.

Authors:  Rui Liu; Christopher G Proud
Journal:  Acta Pharmacol Sin       Date:  2016-01-25       Impact factor: 6.150

4.  Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth In Vivo.

Authors:  Ferah Comert Onder; Nermin Kahraman; Esen Bellur Atici; Ali Cagir; Hakan Kandemir; Gizem Tatar; Tugba Taskin Tok; Goknur Kara; Bekir Karliga; Serdar Durdagi; Mehmet Ay; Bulent Ozpolat
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-30

5.  A high-throughput screening assay for eukaryotic elongation factor 2 kinase inhibitors.

Authors:  Ting Xiao; Rui Liu; Christopher G Proud; Ming-Wei Wang
Journal:  Acta Pharm Sin B       Date:  2016-05-21       Impact factor: 11.413

Review 6.  Eukaryotic Elongation Factor 2 Kinase (eEF2K) in Cancer.

Authors: 
Journal:  Cancers (Basel)       Date:  2017-11-27       Impact factor: 6.639

7.  2-Arylidene-1-indandiones as Pleiotropic Agents with Antioxidant and Inhibitory Enzymes Activities.

Authors:  Olympia Kouzi; Eleni Pontiki; Dimitra Hadjipavlou-Litina
Journal:  Molecules       Date:  2019-12-03       Impact factor: 4.411

Review 8.  Progress in the Development of Eukaryotic Elongation Factor 2 Kinase (eEF2K) Natural Product and Synthetic Small Molecule Inhibitors for Cancer Chemotherapy.

Authors:  Bin Zhang; Jiamei Zou; Qiting Zhang; Ze Wang; Ning Wang; Shan He; Yufen Zhao; C Benjamin Naman
Journal:  Int J Mol Sci       Date:  2021-02-27       Impact factor: 5.923

Review 9.  Eukaryotic elongation factor-2 kinase (eEF2K) signaling in tumor and microenvironment as a novel molecular target.

Authors:  Didem Karakas; Bulent Ozpolat
Journal:  J Mol Med (Berl)       Date:  2020-05-07       Impact factor: 4.599

10.  Discovery of Novel eEF2K Inhibitors Using HTS Fingerprint Generated from Predicted Profiling of Compound-Protein Interactions.

Authors:  Atsushi Yoshimori; Enzo Kawasaki; Ryuta Murakami; Chisato Kanai
Journal:  Medicines (Basel)       Date:  2021-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.